# Emerging-Trends: Executive Laser Report OPHTHALMIC AND MEDICAL LASER HIGHLIGHTS

**June 2013** 

Volume VIII No. 6

# laser@emerging-trends.com

**July 16, 2013** 

We hope that you are surviving this very hot start to the summer. Subscribe to *Executive Laser Report* and get a free subscription to our sister publication, *Trends-in-Medicine*, as well as *Quick Takes*, our weekly news summary. You can even subscribe on our website: **www.trends-in-medicine.com**. Next month we will give you all the news about Abbott's acquisition of OptiMedica.

### **OPHTHALMIC LASER HIGHLIGHTS**

### **Financial News**

- Abbott's board of directors approved a new share repurchase program for up to \$3 billion of common stock and declared a
  quarterly common dividend.
- Iridex converted all outstanding shares of its Series A preferred stock into 1,000,000 shares of its common stock.

### **Other News**

- Bausch + Lomb's Victus femtosecond laser platform was issued a Health Canada medical device license (MDL).
- Carl Zeiss Meditec and Henry Schein Dental formed a distribution partnership in the US for the premium line of Zeiss dental microscopes, OPMI pico and OPMI PROergo, and Zeiss EyeMag dental loupes.
- A Spectralis OCT ophthalmic imaging device from **Heidelberg Engineering** is on its way to the International Space Station (ISS).
- **Lumenis** will launch its ResurFX fractional device at the 22<sup>nd</sup> Annual Conference of the German Dermatologic Laser Society (DDL). In other news, a study published in *JAMA Ophthalmology* showed that treatment with Lumenis' SLT for primary open-angle glaucoma in an underserved population had positive results.
- Five **OptiMedica** Catalys precision laser systems will be used in a French multicenter, randomized clinical study.

# MEDICAL/SURGICAL LASER HIGHLIGHTS

## **Financial News**

- **Cynosure** completed its acquisition of **Palomar Medical Technologies**. Cynosure's stock was added to the S&P SmallCap 600 Index, and Palomar was dropped on June 24.
- Synergetics USA's third-quarter financial results showed increases in sales and net income.

2731 N.E. Pinecrest Lakes Blvd. Jensen Beach, FL 34957 772-334-7409 • Fax 772-334-0856 www.emerging-trends.com

Publisher: Stephen Snyder Managing Editor: Michael Woods Contributing Editor: D. Woods

Editor: Betty Teel

The information and opinions expressed in Executive Laser Report have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright © 2013. This document may not be reproduced without written permission of the publisher.

• **Trimedyne**'s financial results for the quarter and six-month period ended March 31, 2013, showed an increase in revenue and net profit compared to the same time last year.

### **Other News**

- The FDA sent a warning letter to **Alma Lasers**, citing failure to report at least one adverse event. It also issued a Form 483 documenting problems with complaint records and procedures for reviewing and evaluating complaints.
- The FDA gave 510(k) clearance to **AngioDynamics**' Xcela Plus Port family, with pressure activated safety valve (PASV) technology, to Navilyst Medical, an AngioDynamics company. The FDA also gave the green light for the company to conduct a clinical study of its NanoKnife system for the ablation of focal prostate cancer.
- The FDA issued a warning letter to Lisa Laser detailing inadequate documentation of quality procedures and medical device reporting.
- Novadaq Technologies president/CEO Arun Menawat rang the opening bell at the NASDAQ MarketSite in Times Square on May 31.
- Quantel Medical launched its Compact Touch ultrasound biomicroscopy (UBM) system in the US.
- Sciton introduced CelluSmooth, a laser module with proprietary M<sup>3</sup> technology.
- Solta Medical released the Isolaz 2, a next-generation acne therapy device. The company also received 510(k) clearance from the FDA for its fraxel dual 1550/1927 laser system for the treatment of pigmented lesions.

•